Announcement PDF Capital Raising Presentation February 2026 Nigel Lange, CEO & Managing Director ASX Code: OSL Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil, OSL or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com for further information. Not an Offer for Securities Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require for evaluating OSL, its assets, possible valuation, prospects or potential opportunities. Please note that the information contained herein is only of a general nature. It should NOT be relied upon for any evaluation of OSL or for making any investment decision. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act. The distribution of this presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this presentation should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of law. Please refer to the international offer restrictions section of this presentation. This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or in any jurisdiction in which such offer would be illegal. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold , directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. Forward-Looking Statements This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved. A number of important factors could cause the Company’s actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward looking statements, including (without limitation) the risks and uncertainties associated with the ongoing impacts of the Australian and global economic environment and capital market conditions and the risk factors described in the slides titled "Key Risks", with many of these factors beyond the Company’s control. In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise in relation to the underwritten accelerated non-renounceable rights issue and placement to institutional investors of new fully paid ordinary shares in the Company (New Shares) and attaching options. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk. Disclaimer This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. The Company is not obliged to advise of changes or provide updates to any such materials. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents. Any investment in the Company is subject to a number of investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends. Neither OncoSil nor any other entity or person in or associated with OncoSil guarantees any return (whether capital or income) or generally the performance of OncoSil or the price at which its securities may trade. Past performance of the Company cannot be assumed as indicative of the future performance. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined in this presentation. All dollar values are in Australian dollar ($A) terms unless otherwise stated. Figures in this presentation are subject to rounding. The information contained in this presentation is current as of 3 February 2026. 2 Commercialising targeted radiotherapy for pancreatic cancer • OncoSil Medical is commercialising the OncoSil device, an implanted device (brachytherapy) delivering targeted radiation (32P) to pancreatic tumours • OncoSil device is now approved for sale in over 34 countries via CE Mark • Commercial ramp-up has commenced in FY26, driven by significant growth in existing European markets • Increasing market access via label expansion combining new delivery methods and new chemotherapy combinations1 • $2.1 million investment in new Sydney facility supports a potential $98 million revenue opportunity at ~70% Gross Margin at scale • Platform technology can be leveraged into other cancer indications (Bile duct cancer, liver, glioblastoma) • Experienced Board & Management team in the commercialisation of interventional oncology devices >US$4.2bn global addressable market3 • Granted Breakthrough designation in the EU, UK and US with extensive patent coverage across all key geographies • Large global pancreatic cancer patient population of ~510k p.a and targeting locally unresectable population of ~153k (~30%) with the market expected to increase by 37% by 20352 • Negligible survival improvement in over 20 years with <12% survival rates at 5-years and 8.5 months median overall • Existing commercial markets have an addressable total market of $898 million annually • Patient recruitment completed for PANCOSIL & TRIPP-FFX trials, targeting:  Percutaneous delivery to drive market access and clinical adoption globally  Label expansion in addition to standard-of-care chemotherapy (FOLFIRINOX) Significant achievements over CY25 • Received MDR Approval which includes the removal of all existing post-market restrictions (OSPREY registry) • Patient recruitment completed for PANCOSIL study and preliminary data presented at CIRSE 2025 Congress (a groundbreaking delivery method for OncoSil device) • Patient recruitment completed for TRIPP-FFX trial (to expand OncoSil device label with additional chemotherapy combination) • Second manufacturing facility in Sydney, Australia activated and ready to undergo validation. • Constructive discussions with US FDA on the regulatory pathway for OncoSil device in Bile Duct Cancer (dCCA) • German Federal Joint Committee (G-BA) tender process underway to appoint a CRO • First patient treatments completed at Germany and Portugal Executive Summary References: 1. Subject to Regulatory Approval. 2. Globocan 2022 data . 3 179,000 global locally advanced pancreatic cancer population multiplied by US$24k average price 3 Catalyst rich CY26 • Strong commercial momentum and growing hospital adoption across existing markets: Austria, Germany, Greece, Israel, Italy, Portugal, Spain, Turkey, and the UK • Tender finalisations expected to drive significant revenue growth • Finalisation of G-BA tender process to appoint CRO and commence recruitment for the G-BA trial • Results of the TRIPP-FFX Study (1H CY26) • Label expansion targeting: o Percutaneous delivery for Interventional Radiology (PANCOSIL study) – 2H CY26 o Combination with standard-of-care chemotherapy - FOLFIRINOX (TRIPP-FFX study) – 2H CY26 • First commercial production at Macquarie Park, Sydney manufacturing facility (2H CY26) • Publication of real-world clinical data to support market access and drive adoption Equity Raising • Equity raising of $8.0 million, comprising: o A ~$3.2 million Institutional Placement through the issuance of approximately 4.7 million New Shares (“Tranche 1 Placement”) in accordance with the Offeror’s existing placement capacity under ASX Listing Rule 7.1 and 7.1A; o A ~$2.8 million Institutional Placement through the issuance of approximately 4.1 million New Shares, subject to shareholder approval at an Extraordinary General Meeting (“EGM”) to be held on or around March 2026 (“Tranche 2 Placement”); together, the Tranche 1 Placement and Tranche 2 Placement are the “Placement” and o A ~$2.0 million (before costs) 1-for-6.4 pro rata non-renounceable entitlement offer (“Entitlement Offer”) through the issuance of approximately 2.9 million New Shares Together, the Placement and Entitlement Offer are the “Offer” • Shares issued under the Offer will have one (1) free attaching option for every one (1) New Shares issued (“Attaching Options”). The Options are intended to be listed on the ASX with an exercise price of $0.90 with an expiry date of 30 June 2027 • Following completion of the Offer, OSL will have a pro forma cash balance of ~$12.0 million ($4.7 million pro forma closing cash at 31-Dec-25 and RDTI received in Jan-26, plus net proceeds of the Offer of ~$7.3 million) Executive Summary (cont.) 4 Reinforcing the significant unmet need for new therapeutic approaches Pancreatic Cancer Treatment Has Seen Limited Guideline Evolution 5 First-Line (Initial Therapy) LAPC Second-Line LAPC Disease Progression Disease Progression Best Supportive Care Experimental Therapies FOLFIRINOX chemotherapy (2011) Gemcitabine + nab-paclitaxel chemotherapy (2013) OncoSil device is chemotherapy agnostic; immunotherapies (mono therapy / combination therapies) have shown no survival benefit – hence, no incorporation into treatment guidelines (NCCN, ESMO) – significantly lower risk of product obsolescence Guideline recommendations have remained largely consistent across multiple annual updates, only change has been NALIRIFOX in 2024 – 10+ years after initial clinical data for other regimens NCCN – National Comprehensive Cancer Network; ESMO – European Society for Medical Oncology FOLFIRINOX chemotherapy (2011) Gemcitabine + nab-paclitaxel chemotherapy (2013) OncoSil 1st line in LAPC Growing number of active implanting centres to drive revenue momentum Expanding Commercial Footprint Across Key European Markets Germany • 2 hospitals already opened before G-BA trial • 40 new hospitals expected to start by 1H CY27 • Expecting to start recruitment in G-BA trial 1H CY26 • Patients’ ineligible for trial may still be treated commercially provided they are candidates for OncoSilTM treatment Spain • Largest revenue-contributing market • 6 hospitals routinely ordering and treating with OncoSil • 6 new hospitals are expected to start in CY26 • Strong referral acceptance from oncologists and surgeons Italy • 5 hospitals routinely ordering and treating with OncoSil • 4 new hospitals are expected to start in CY26 • OncoSil adopted by two leading hospitals — University of Verona and San Camillo Forlanini Hospital • Revenue contribution expected to increase significantly in 1H CY26 following finalisation of individual tender agreements Turkiye • 4 hospitals routinely ordering and treating with OncoSil • 5 new hospitals are expected to start in CY26 • Cumulatively 45% resection rate in real-world setting • One of the largest potential markets in oncology and nuclear medicine treatments • Ongoing referral education initiatives to increase patient flow 6 8 12 17 20 26 39 4 5 3 6 13 19 0 10 20 30 40 50 60 70 1H CY24(A) 2H CY24(A) 1H CY25(A) 2H CY25(A) 1H CY26(E) 2H CY26(E) Commercially Active Implanting Centres Existing New CAGR 94% Population ~ 84 million Pancreatic Cancer Incidence p.a.1 22,587 Locally Advanced Pancreatic Cancer p.a. 6,776 Market Opportunity p.a. $264 million System-funded clinical evidence generation alongside ongoing commercial use Germany: Capital-Efficient Phase III with Commercial Momentum References: 1. Globocan 2025 data 2.https://www.aok.de/pp/hintergrund/mindestmengen/mindestmengen-transparenzkarte- 2026/ 3. The centres with appropriate nuclear medicine facilities capable of delivering OncoSilTM device The top 40 German pancreatic cancer centres performed approximately 4,400 complex pancreatic surgeries in 20242, accounting for ~40% of all such procedures nationwide. These high-volume centres represent our primary targets for commercial adoption, alongside their anticipated participation in the G-BA trial3. Abbreviation: G-BA: Gemeinsamer Bundesausschuss (Federal Joint Committee). 7 G-BA Market Opportunity 8 Est. LAPC patients within G-BA Centres (n=40) 4,400 Est. LAPC patients to be recruited into G-BA Trial1 280 1. Randomised 1:1 to the OncoSil + chemotherapy arm versus chemotherapy alone arm 2. G-BA sites are already NUB approved. No additional reimbursement approval needed to treat commercially. 4,120 Est. pool of patients potentially able to receive OncoSil outside of trial within G-BA sites (eligible for reimbursement2) $168 million (annually) Serviceable market opportunity with high sales synergies How the G-BA Initiative Accretes Significant Value in OncoSil Direct Sales Revenue Over Trial Period1 $5.6 million $6.5 million Potential ancillary commercial sales at G-BA sites over Trial Period2 $35.0 million Est. cost if OncoSil Sponsored Identical G-BA Trial Total est. value accretion $47.1 million 9 Additional Actual + Potential Intangible Benefits • Level 1 evidence trial (gold standard for regulators/clinicians) • Positive data provides National Reimbursement in Germany • Incorporation into German consensus treatment guidelines • Potential for other European consensus treatment guidelines • Important for Health Technology Assessments (HTAs) re: further reimbursement in additional markets (e.g. NICE UK, HAS France) • Significantly increases trained clinicians in Germany, driving future adoption patterns 1. At the commercial selling price per OncoSil treatment 2. Trial recruitment expected to be over a two-year period, commencing 1H CY26 Expanding Physician Access and Improving Procedural Economics Expanded Label to Facilitate Percutaneous Administration Preliminary results rom the PANCOSIL Investigator Initiated Study, presented at the CIRSE 2025, demonstrate that CT-guided percutaneous administration of OncoSilTM is safe and feasible. Why Percutaneous Administration Matters • Expanded physician access: Broadens treating base to include Interventional Radiologists (IRs) • Compelling healthcare economics: • 10–20-minute procedure time • Outpatient setting* • Conscious sedation (no general anaesthesia) • High procedural familiarity: IRs experienced in minimally invasive, tumour-directed radiation therapies (e.g. SIR-Spheres®, TheraSphereTM, QuiremSpheres®) • Portfolio strategy: Attractive tuck-in product for surgical and interventional offerings * where permitted 1. BSI is a Notified Body under the EU Medical Device Regulation (EU MDR).That means BSI is one of the authorised independent organisations that assesses medical devices and can issue/maintain MDR certificates after a conformity assessment. The certification supports the manufacturer’s ability to apply/maintain CE marking for the device in its approved indication/scope. 10 European IR Market Dynamics > 5,000 Interventional Radiologists CAGR 7-8% into 2030 ~ 2,000 Interventional Radiologists in Germany Active Tumour Board Participation • OncoSil will file a change notification with the British Standards Institute (BSI) for its existing regulatory approval (CE Mark) in 1H CY261 • Anticipate regulatory acceptance in 2H CY26 & commence on-label marketing of OncoSil device for percutaneous patient treatment Early real-world experience demonstrates strong tumour response and multidisciplinary execution in pancreatic cancer High Resection Rates at Ankara Bilkent City Hospital  Largest hospital in Türkiye, with >3,700 beds  Among the first centres in Türkiye to adopt the OncoSil device in routine clinical practice  Strong multidisciplinary collaboration across Oncology, Surgery, Gastroenterology, and Nuclear Medicine  To date, 6 pancreatic cancer patients treated with the OncoSil device  High volume pancreatic cancer treatment centre: >500 patients undergoing surgery from Feb 2019 – Dec 2024 ($2.2 million annual potential)1 Tumour Response (n=6 evaluable patients) Complete response (CR) 1/6 (16.6%) Partial response (PR) 4/6 (66.6%) Stable disease (SD) 1/6 (16.6%) One patient received OncoSilTM therapy in Jan 2026 and is not included in the response and resection analysis. 5 patients (83%) underwent surgical resection Key Success Factors  Comprehensive site training and ongoing clinical support  Effective multidisciplinary decision-making  Rigorous patient selection 11 References: 1. Martlı HF, et al., Clinicopathological features of patients undergoing surgery for pancreatic cancer with very early postoperative recurrence. World J Gastrointest Surg. 2025 Nov 27. Distributor market. Manufacturing / Clinical Trial Investment Nears Completion 12 Second Manufacturing Facility – Macquarie Park, Sydney Total Investment $2.1 million | Estimated Remaining in FY26 $0.8 million² Clinical Trial Investment (TRIPP-FFX, PANCOSIL) Total Investment $8.1 million* | Estimated Remaining to FY27 $2.0 million OncoSil Has Invested Significantly into Building Capability and Generating Clinical Evidence to Drive Commercial Adoption and Regulatory Changes • Investments expected to largely complete in FY26 – cumulative investment of $7.4 million to 1H FY26 • Launch pad for more sustainable cost base on growing sales profile from FY27 • Realigning our operations to optimise resources and position the business to fully leverage the market opportunity. These investments support the business’ transition from a research company to a commercially focused organisation. • Capacity to support potential revenue of $98m at ~70% Gross Margin1 * excluding COGS 1. Based on one batch per week, can increase to two batches per week with no additional investment at an average European selling price of $37.7k 2. Excludes costs associated with adding facility as a critical manufacturer with notified body. M&A Activity in the Interventional Radiology Space 13 Significant M&A Activity in IR/Interventional Oncology since 2018 Acquirer Target [Embolic Bead Business] Alicon (China) Expected commercial catalysts over the next 18 months Upcoming Milestones 14 1H CY26 2H CY26 2H CY25 1H CY27 Full data release of OSPREY Registry (real world data) Regulatory submission for percutaneous application Commercial launch of percutaneous application* * Subject to change notification approvals Regulatory submission for label expansion to include FOLFIRINOX First commercial dose supply from Sydney, Australia facility Label extension with FOLFIRINOX chemotherapy* Recruitment starts in G-BA trial Full data release of TRIPP-FFX clinical study First patient treatments at Germany, Portugal and the UK First hot production test run at Sydney facility Completion of recruitment at TRIPP-FFX and PANCOSIL trials Expansion in new markets (South East Asia) Expansion in new markets (France, Hong Kong) Further feedback expected from TGA Completion of regulatory processes and launch in MENA Offer Details Offer Details 27 Offer Structure • OncoSil has announced the launch of an equity raising of approximately A$8.0 million, comprising: o A $3.2 million Tranche 1 Placement of approximately 4.7 million New Shares in accordance with the Company’s existing placement capacity under ASX Listing Rule 7.1 and 7.1A, and a $2.8 million Tranche 2 Placement of approximately 4.1 million New Shares, subject to shareholder approval at an EGM to be held on or around March 2026; and o A $2.0 million 1-for-6.4 Entitlement Offer of approximately 2.6 million New Shares • New Shares issued under the Offer will include a 1 for 1 free attaching option, exercisable at A$0.90 expiring on 30 June 2027 • Approximately 11.8 million New Shares will be issued under the Offer (comprising approximately 62% of OncoSil’s existing issued capital • Record date for the Entitlement Offer is at 7:00pm (Sydney Time) on Friday, 6 February 2026 Offer Price • New Shares under the Offer will be issued at $0.68 per New Share (“Offer Price”), representing; o A 15.0% discount to last close of $0.80 as of Thursday, 29 January 2026 Entitlement Offer • Under the Entitlement Offer, eligible securityholders are invited to subscribe for 1 New Share for every existing 6.4 shares held (“Entitlement”) held as of 7.00pm (Sydney time) on Friday, 6 February 2026 (“Record Date”). • The Entitlement Offer is non-renounceable, and Entitlements will not be tradable or otherwise transferable. Eligible shareholders who do not take up their Entitlement under the Entitlement Offer in full or in part, will not receive any value with respect to those Entitlements not taken up. • Eligible Shareholders that take up their full Entitlement may also apply for additional New Shares (“Additional Shares”), subject to the Company’s scale back policy as set out in the transaction specific prospectus prepared in relation to the Offer and lodge with ASIC on Friday, 6 February 2026. Ranking • New Shares issued under the Offer will rank equally with existing fully paid ordinary shares on issue in OncoSil Attaching Options • New Shares issued under the Offer will include a 1-for-1 free attaching option, each exercisable into 1 New Share, at an exercise price of $0.90 each, expiring on 30 June 2027 (“Attaching Options”). • The New Shares and Attaching Options will be offered under a transaction-specific prospectus pursuant to section 713 of the Corporations Act 2001 (Cth) (“Corporations Act”) (“Prospectus”). • Any Shares issued upon the future exercise of Attaching Options will rank equally with the Shares on issue at the date of the Prospectus. Lead Manager and Underwriter • Bell Potter Securities Limited (“Bell Potter”, “Lead Manager” and “Underwriter”)1 is acting as Sole Lead Manager to the Offer. The Entitlement Offer only is underwritten by the Underwriter. Equity Raising of $8.0 million via a $6.0 million Placement and $2.0 million Entitlement Offer References: 1. Subject to shareholder approval, Bell Potter will receive Options on the same terms as the Offer, equal to 1.0% of the total number of fully paid ordinary shares in the Company following completion of the Offer. Use of Funds & Timetable Sources (A$m) Placement $6.0 Entitlement Offer $2.0 Total $8.0 28 Uses (A$m) Ongoing clinical investment $2.0 Investment in manufacturing facility $1.0 Sales and marketing investment $2.5 Market access investment $1.2 General working capital and costs of the Offer $1.3 Total $8.0 Timetable Trading halt Friday, 30 January 2026 Trading halt lifted and recommence trading on an ex-entitlement basis Tuesday, 3 February 2026 Record Date for Entitlement Offer 7:00pm Friday, 6 February 2026 Settlement of Tranche 1 Placement Friday, 6 February 2026 Allotment of New Shares issued under the Tranche 1 Placement Monday, 9 February 2026 Entitlement Offer booklet dispatched and Entitlement Offer opens Wednesday, 11 February 2026 Entitlement Offer closes Tuesday, 10 March 2026 Results of the Entitlement Offer announced to ASX and notification of shortfall to sub-underwriters Thursday, 12 March 2026 EGM to approve Tranche 2 Placement Shares and Placement Options Thursday, 12 March 2026 Settlement of Entitlement Offer and Tranche 2 Placement Monday, 16 March 2026 Issue of Entitlement Offer and Tranche 2 Placement Tuesday, 17 March 2026 Holding statements dispatched for New Shares issued under the Entitlement Offer and Tranche 2 Placement Wednesday, 18 March 2026 References: All dates are subject to change and are indicative only. OncoSil, in consultation with the Lead Manager, reserves the right to vary these dates without prior notice, all references are to AEDT The above table is a statement of current intentions as at the date of this Presentation. Investors should note that, as with any budget, the allocation of funds set out in the above table may change depending on a number of factors, including the outcome of sales performance, operational and development activities, regulatory developments, and market and general economic conditions. In light of this, OncoSil reserves its right to alter the way the funds are applied. Appendix How the OncoSil Device Works 30 Video Link 4 clinical studies supporting commercialisation demonstrate efficacy, safety and tolerability in LAPC Growing Body of Evidence Unresectable Locally Advanced Pancreatic Cancer (LAPC) Unresectable LAPC or Borderline-Resectable LAPC Metastatic PDAC Study PanCO Study 1 OncoPaC-1 Study2 Propensity Score Weighted Landmark Analysis 3 Comparative Analysis 4 Metastatic Study 5 Treatment OncoSil + Chemotherapy a OncoSil + gemcitabine/ nab-paclitaxel OncoSil + Chemotherapy b Chemotherapy b (± Chemoradiotherapy) OncoSil + Chemotherapy b Chemotherapy b + SBRT OncoSil + Chemotherapy a Sample Size 42 (50 ITT) 9 50 35 at landmark 54 51 at landmark 42 59 14 Local Disease Control Rate at 16 weeks 90.5% 77.8% nr nr nr nr 100% Objective Response Rate 31.0% 22.2% nr nr nr nr 57.1% Disease Control Rate 100% 100% nr nr nr nr 100% Surgical Resection with Curative Intent 23.8% 0 28.6% 12.1% 22% 0% 7.1% Downstaging 33.3% not reported 31.4% 13.6% 23.8% 3.4% 7.1% Local PFS, median 9.8 months 27.3 months 15.6 months 9.3 months 18.9 months 14.1 months 12.2 months Distant PFS or PFS (PFS), median 9.3 months PFS 12.2 months PFS 14.2 months 10.7 months 20.0 months 14.0 months 9.2 months PFS Overall Survival, median 15.5 months 27.3 months 20.0 months 12.3 months 22 months 14 months 13.8 months p=0.002 p=